Screen the entire global market — including names the crowd has left for dead — by quality, growth, returns and valuation.
Every subsector ranked on valuation, income, returns and leverage, computed from our own company financials with a book-value NAV proxy. Click a subsector for its full report.
The financials and ratios on this page come straight from the filings and are live. The judgement — what it is worth, and what would break it — is what we add.
A fast read of the filings to help decide whether this is worth a closer look. Thin by design.
See plansA full research report on the company and everything around it — the filings, the competitors, the news, the industry, the economy and the regulatory backdrop — with a full valuation model, fair value, and bear, base and bull case scenarios.
Buy the deep research · $99Put a question to the analyst and get an answer grounded in this company's own filings and our research — "what breaks the thesis?", "how much of profit goes to interest?"
Included from Premium →It takes up to 3 hours and covers the filings, the competitors, the news, the wider industry, the economy it sits in, the regulatory backdrop, and a full model and a fair value with sensitivities. It runs in the background — we will let you know when it lands, so you do not need to keep this page open.
Annual financial statements as reported, going back as far as the data allows.
| $m | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E |
|---|
| $m | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E |
|---|
| $m | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E |
|---|
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E |
|---|
Who bought and sold, at what price, and how much of their own holding it was — from SEC Form 4, UK PDMR and EEA MAR Article 19 notifications, with each insider's last-reported position and disclosed major holders.
A valuation is produced by the company research pipelines — the flash thesis carries one, and a deep dive replaces it with a fuller model. Neither has run for this company yet.
The 6 investable Drug Manufacturers - General industry peers closest in size, largest first. Market caps are shown in USD so the set compares like with like; the multiples are currency-neutral. The median is taken across the PEERS only — it is what this company is being compared to — and per column, over the peers that actually report each measure.
| Company | Mkt cap (USD) | P/E | EV/FCF | P/B | ROIC | Op margin | Div yield |
|---|---|---|---|---|---|---|---|
| Sanofi SAN | $109.7bn | 14.5× | 16.0× | 1.4× | 6.0% | 11.8% | 5.0% |
| GSK GSK | $105.4bn | 16.3× | 13.5× | 4.8× | 18.6% | 19.5% | 3.4% |
| Bayer AG NA BAYN | $54.9bn | — | 18.1× | 1.9× | 6.5% | 11.2% | 0.3% |
| GSK G1SK34 | $44.8bn | 5.9× | 6.9× | 2.0× | 18.6% | 19.5% | 8.0% |
| Biogen BIIB | $36.8bn | 137.8× | 20.7× | 2.0× | 5.6% | 12.9% | 0.0% |
| Orion Oyj B ORNBV | $15.7bn | 26.6× | 58.2× | 10.9× | 34.5% | 33.4% | 1.6% |
| Orion Oyj A ORNAV | $15.7bn | 26.5× | 58.1× | 10.9× | 34.5% | 33.4% | 1.6% |
| Peer median | $49.8bn | 16.3× | 17.1× | 3.4× | 18.6% | 19.5% | 2.5% |
A comparable set says what the market is paying for similar businesses today, not what any of them is worth. It is a cross-check on the model above, not a substitute for it.
A full deep-dive (business, moat, risks, valuation and scenarios) hasn't been generated for this company yet.
Source documents straight from the database — click to read the raw filing or release — beside the issuer's own releases and dated events, newest first. Our read on what matters lives in Recent developments.
Upcoming and recent investor events — results, AGM, dividend and ex-dividend dates — from the company's own investor calendar.
Every place this issuer trades — the home listing, foreign cross-listings and depositary receipts (ADR/CDR/BDR), plus any separate share classes. The screener shows one canonical line per company; the rest live here.
| Listing | Exchange | Ticker | Currency | Price | Type |
|---|
Interactive price chart with the common technical-analysis overlays and indicators — moving averages, Bollinger Bands, volume, RSI and MACD — plus an at-a-glance momentum summary. Use the chart's own toolbar to add or remove studies, change timeframe, or search a different listing.
A note on method: PrimerIQ's research is built bottom-up from the filings — what a business earns and what it's worth. The charts below read price history, not the business; we include them because many investors want them, not because they drive our valuation. Treat them as one lens among several.
Relative strength percentile: 90 vs market, 91 vs industry. Momentum rank is a 0–100 percentile across 39,551 companies — one lens, not a valuation signal.
Charts and technical data by TradingView. Not investment advice.
The webcast audio itself, transcribed in full, with the structural signals the transcript text alone loses — how scripted rather than spontaneous the language is, where management hesitated longest, and which answers were most hedged.
Included from Premium →Select a filing on the left to read it here.
Select a filing to view its raw text.